Surgery Partners Q4 revenue beats estimates

Surgery Partners

02/03/2026 21:13

Overview

Surgical facility operator's Q4 revenue rose 2.4%, beating analyst expectations

Adjusted EPS for Q4 missed analyst expectations

Company authorized $200 mln share repurchase program on Feb. 26

Outlook

Surgery Partners projects 2026 revenue between $3.35 bln and $3.45 bln

Company expects 2026 Adjusted EBITDA of at least $530 mln

Surgery Partners focuses on higher-acuity procedures to capture market momentum

Result Drivers

SAME-FACILITY REVENUES - Increased 3.5% in Q4, driven by a 2.1% rise in revenue per case and a 1.3% increase in same-facility cases

MARGIN PRESSURE - CFO Dave Doherty noted margin pressure impacted full-year performance, with a focus on operational improvements for 2026

Company press release: ID:nGNX41rXVx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$885 mln
$866.47 mln (11 Analysts)
Q4 Adjusted EPS
Miss
$0.12
$0.30 (11 Analysts)
Q4 Adjusted EBITDA
Miss
$156.90 mln
$169.24 mln (11 Analysts)
Q4 Adjusted EBITDA Margin
17.70%
Q4 Operating Income
$110.20 mln
Q4 Pretax Profit
$42.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Surgery Partners Inc is $28.00, about 80.6% above its February 27 closing price of $15.50

The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)